NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TCRT

Alaunos Therapeutics Inc

Jul 11 • 04:00PM ET

4.99

Dollar change +0.06
Percentage change 1.15	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NTLA EDIT BEAM PGEN KPTI FATE ADAP SGMO IMTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.54	Insider Own	24.21%	Shs Outstand	1.60M	Perf Week	-0.20%
Market Cap	9.87M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.50M	Perf Month	54.25%
Enterprise Value	9.55M	PEG	-	EPS next Q	-	Inst Own	3.58%	Short Float	5.73%	Perf Quarter	94.16%
Income	-4.07M	P/S	987.00	EPS this Y	-	Inst Trans	55.81%	Short Ratio	2.53	Perf Half Y	165.43%
Sales	0.01M	P/B	7.55	EPS next Y	-	ROA	-99.82%	Short Interest	0.09M	Perf YTD	161.94%
Book/sh	0.66	P/C	30.84	EPS next 5Y	-	ROE	-139.06%	52W High	6.80 -26.62%	Perf Year	-21.73%
Cash/sh	0.16	P/FCF	-	EPS past 3/5Y	62.43% 51.16%	ROIC	-384.78%	52W Low	1.31 279.84%	Perf 3Y	-97.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-70.71% -	Gross Margin	-2380.00%	Volatility	5.19% 14.47%	Perf 5Y	-98.97%
Dividend TTM	-	EV/Sales	955.00	EPS Y/Y TTM	84.81%	Oper. Margin	-41630.00%	ATR (14)	0.43	Perf 10Y	-99.70%
Dividend Ex-Date	-	Quick Ratio	1.00	Sales Y/Y TTM	66.67%	Profit Margin	-40710.00%	RSI (14)	66.19	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.00	EPS Q/Q	36.21%	SMA20	10.91%	Beta	-0.78	Target Price	1125.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	100.00%	SMA50	44.51%	Rel Volume	0.75	Prev Close	4.93
Employees	1	LT Debt/Eq	0.00	Earnings	-	SMA200	104.78%	Avg Volume	33.92K	Price	4.99
IPO	Aug 22, 2005	Option/Short	No / Yes	EPS/Sales Surpr.	-14.29% -	Trades		Volume	25,554	Change	1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Resumed	Wells Fargo	Overweight	$3

Jun-23-25 08:00AM	Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering (GlobeNewswire)
Jun-18-25 09:52AM	PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies (GlobeNewswire) +9.18%
May-14-25 08:00AM	PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (GlobeNewswire)
Oct-11-24 08:57AM	Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy (TipRanks)
May-15-24 10:55PM	TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.39%
12:52PM	Loading…
Apr-08-24 12:52PM	TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Dec-18-23 07:57AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? (InvestorPlace) +26.15%
Nov-14-23 07:56AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today? (InvestorPlace) -10.59%
07:30AM	Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives (GlobeNewswire)
Aug-14-23 04:05PM	Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives (GlobeNewswire) -64.68%
Jun-29-23 07:00AM	Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire) +14.30%
May-25-23 05:00PM	Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -16.65%
May-10-23 07:00AM	Alaunos Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 08:30AM	Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-26-23 12:30PM	Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) +6.57%
07:00AM	Loading…
Mar-30-23 07:00AM	Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors (GlobeNewswire)
Mar-29-23 05:30PM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April (GlobeNewswire) +6.72%
Mar-07-23 07:00AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:01PM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 (GlobeNewswire)
Feb-17-23 05:47AM	Alaunos Therapeutics, Inc.'s (NASDAQ:TCRT) largest shareholders are individual investors with 58% ownership, institutions own 22% (Simply Wall St.)
Jan-09-23 08:30AM	Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 (GlobeNewswire)
Nov-29-22 09:01AM	Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -22.78%
Nov-28-22 04:01PM	Alaunos Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.84%
Nov-14-22 07:00AM	Alaunos Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.48%
Nov-08-22 08:30AM	Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Nov-07-22 08:00AM	Alaunos Therapeutics to Present Data Highlighting its hunTR TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting (GlobeNewswire)
Sep-21-22 08:30AM	Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) -20.87%
Sep-07-22 08:30AM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +18.21%
Sep-06-22 08:00AM	Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy (GlobeNewswire)
Aug-24-22 03:00PM	Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) +20.00%
07:00AM	Loading…
Aug-15-22 07:00AM	Alaunos Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +18.18%
Aug-08-22 08:50AM	Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-04-22 05:00PM	Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations (GlobeNewswire) +8.39%
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +13.45%
Jun-30-22 07:07AM	Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt In A Risky Way? (Simply Wall St.)
Jun-27-22 08:00AM	Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 (GlobeNewswire) +17.27%
Jun-01-22 08:30AM	Alaunos Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) -8.63%
May-26-22 05:01PM	Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +11.09%
May-16-22 07:30AM	Alaunos Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -15.15%
May-12-22 11:48AM	Insiders who placed huge bets on Alaunos Therapeutics, Inc. (NASDAQ:TCRT) earlier this year would be disappointed with the 27% drop (Simply Wall St.) +5.89%
May-10-22 08:30AM	Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.16%
May-09-22 08:30AM	Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire)
May-02-22 04:31PM	Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -7.28% +12.66%
08:30AM	Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors (GlobeNewswire)
Mar-30-22 07:30AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-22-22 01:58PM	What Percentage Of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Do Insiders Own? (Simply Wall St.)
Mar-16-22 08:30AM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022 (GlobeNewswire) +8.41%
Mar-08-22 04:05PM	Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) +21.63%

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vieser Jaime	Director	Dec 31 '24	Sale	2.01	3,000	6,022	25,894	Jan 03 04:34 PM
Vieser Jaime	Director	Dec 31 '24	Proposed Sale	2.17	3,000	6,510		Dec 31 05:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRT

Alaunos Therapeutics Inc

Upgrade your FINVIZ experience